STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Complete Title: A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated with Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients with Triple Negative Breast Cancer

Trial Phase: II

Investigator: Nora Disis

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system`s response to STEMVAC.

Keywords:

Breast Cancer
Triple Negative Breast Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.